Latest Research Highlights (Canadian + International, 2022–2025)

Basic Vigora Information

• INN (International Nonproprietary Name): Sildenafil
• Brand Names Available In Canada (English): Not specified
• ATC Code: G04BE03
• Forms & Dosages: Tablet (film-coated) 25mg, 50mg, 100mg; Oral Suspension 10mg/mL (for PAH, not ED); Chewable tablets 50mg/100mg (some generics)
• Manufacturers In Canada (English): Not specified
• Registration Status In Canada (English): Not specified
• OTC / Rx Classification: Prescription (Rx) only

Recent syntheses from 2022–2025 continue to support sildenafil’s established efficacy for erectile dysfunction and confirm its safety when used as indicated.

On‑demand dosing typically shows a clinical onset of about 30–60 minutes, with many patients reporting improved erectile function versus placebo in controlled trials and observational cohorts.

Canadian observational cohorts and international trials report comparable response rates across age groups, although adverse‑event reporting is higher among people with polypharmacy or cardiovascular disease.

Emerging Canadian data highlight rural access gaps and an increased uptake of telehealth prescribing since 2020, which affects how patients obtain ED treatment.

Data Highlights: Response rate range reported across recent syntheses generally indicates clinically meaningful improvement in erectile function for a majority of patients when used as directed.

• ED Response: Measurable improvement in erectile function scores or successful intercourse attempts after treatment.
• Treatment‑Emergent Adverse Events: Side effects starting after treatment initiation, commonly headache or flushing.

Canadian patient‑centred recommendations emphasise shared decision‑making and culturally safe care, including bilingual consent materials and specific attention to Indigenous and visible‑minority communities.

Clinical Effectiveness In Canada (Health Canada Monographs & DIN Context)

Health Canada recognises sildenafil for erectile dysfunction and sildenafil (as Revatio) for pulmonary arterial hypertension, both as prescription medicines.

Product monographs and Health Canada labelling describe on‑demand ED dosing and the distinct PAH regimen for Revatio.

Vigora is a well‑known Indian brand manufactured by Zydus Cadila and widely available online, but it is generally not listed among standard Canadian market authorisations and should be verified against Health Canada’s Drug Product Database and DIN assignments before recommending cross‑border purchases.

• Pharmacies such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs routinely dispense Health Canada‑approved sildenafil generics after confirming the DIN.
• In Quebec and federally, bilingual labels and patient leaflets are required for packaged drugs.

When counselling, pharmacists should confirm DIN assignments and advise patients that cross‑border purchases may not carry the same regulatory protections.

Indications & Expanded Uses (Approved Vs Off‑Label In Canada)

Sildenafil is approved in Canada for erectile dysfunction with on‑demand dosing, and sildenafil (Revatio formulation) is approved for pulmonary arterial hypertension with a three‑times‑daily regimen.

Off‑label uses reported in practice include investigational approaches for female sexual arousal disorders and some vasospastic conditions, but these uses lack robust Health Canada approval and require specialist oversight and informed consent.

• Approved Vs Off‑Label: Approved uses are indications authorised by regulators and listed on the product monograph; off‑label uses are clinician‑directed uses not specified in the monograph and should be supported by evidence and consent.

Children: sildenafil is not indicated for ED in those under 18.

Pediatric sildenafil for PAH is prescribed only by specialists with age‑appropriate dosing.

• Refer to a specialist for cardiac disease, recent myocardial infarction or unstable angina.
• Refer for significant hypotension or complex polypharmacy.
• Refer if the patient is taking nitrates or recreational nitrites.

Always document informed consent, provide bilingual materials on request, and check provincial coverage and exceptional access routes for off‑label prescribing.

Composition & Brand Landscape (Active Ingredient, Brands, Generics, DIN References)

The active ingredient is sildenafil citrate, also listed by INN as sildenafil.

Market options include Pfizer’s Viagra and multiple Health Canada‑approved generics marketed under DINs.

• Common forms: film‑coated tablets 25/50/100mg and Revatio oral suspension 10mg/mL for PAH.
• Pharmacies must verify DIN and lot traceability before dispensing and should avoid recommending cross‑border or unverified online sources due to authenticity concerns.

Quebec and federal rules require French labelling; pharmacies verify DINs and lot numbers at dispensing time.

Contraindications & Special Precautions (Health Canada Advisories, High‑Risk Canadian Groups)

Use is absolutely contraindicated with nitrate medications and in patients with known hypersensitivity to sildenafil or excipients.

Health Canada advises caution in unstable cardiovascular disease, recent myocardial infarction, severe hypotension and severe heart failure.

• Absolute Contraindications: Concomitant nitrates, known hypersensitivity, severe cardiovascular instability.
• Relative Contraindications / Caution: Aortic stenosis, arrhythmias, severe hepatic or renal impairment, history of priapism disorders, bleeding disorders.

Emergency Red Flags: Priapism lasting more than four hours, sudden vision loss, sudden hearing loss, syncope or chest pain require immediate medical attention.

Special Canadian populations needing explicit risk–benefit discussions include elderly patients with polypharmacy, residents of rural or remote communities with limited emergency access, and Indigenous patients with higher baseline cardiovascular comorbidity.

Pharmacists should confirm all current medicines including over‑the‑counter nitrates and recreational substances such as amyl nitrite (“poppers”) and counsel on urgent care for prolonged erections.

Dosage Guidelines (Standard Canadian Dosing And Special Adjustments)

The usual adult starting dose for erectile dysfunction is 50mg taken about 30–60 minutes before sexual activity, with adjustment between 25–100mg based on response and tolerability.

No more than one dose should be taken in a 24‑hour period for ED dosing unless specifically instructed by a prescriber.

For pulmonary arterial hypertension, the Revatio dosing is 20mg three times daily and uses a distinct formulation and indication.

• Start lower (25mg) in hepatic or severe renal impairment and when co‑administered with strong CYP3A4 inhibitors.
• Elderly patients do not have a routine age‑based reduction but should be started on the lowest effective dose and monitored for side effects.

Prescriptions should clearly state dose and maximum frequency and pharmacists should counsel on expected onset and duration.

Interactions Overview (Drugs, Food, And Canadian Lifestyle Factors)

The most critical interaction is with nitrates, which can cause severe hypotension when combined with sildenafil.

Strong CYP3A4 inhibitors such as some protease inhibitors and azole antifungals raise sildenafil exposure and require dose adjustment.

• Pharmacists should screen for OTC remedies and herbal products marketed for sexual performance that may contain unknown or risky ingredients.
• Patients ordering Vigora online should be counselled that formulations and excipients can vary and that importation rules and authenticity should be verified.

Cultural Perceptions & Patient Habits (Canadian Forums, Urban Vs Rural Access)

Many Canadian men seek discreet, price‑transparent care and appreciate bilingual resources when available.

Privacy and stigma remain significant barriers, especially in small towns and Indigenous communities.

• Urban patients often use walk‑in clinics and chain pharmacies for same‑day access.
• Rural patients may rely on telehealth and mail delivery but face longer specialist wait times and confidentiality concerns in small communities.
• Telehealth has expanded access since 2020, but follow‑up and authenticity of online suppliers can be challenging.

• E‑Prescription: Electronic prescription sent from clinician to pharmacy for dispensing or mail delivery.
• Mail Delivery: Pharmacy ships medication to the patient’s address; discreet packaging commonly offered.
• Community Pick‑Up: Patient collects medication at local pharmacy, allowing face‑to‑face counselling.

Clinicians should offer culturally safe communication, provide French materials where requested, and explain provincial coverage up front to avoid surprises.

Availability & Pricing Patterns (Major Chains, Online, Cross‑Border Notes)

Within Canada, Viagra and multiple Health Canada‑approved generics are dispensed at major chains and independent pharmacies, with price variation by brand, strength and pharmacy markup.

Online Canadian pharmacies require a prescription and typically list DIN‑verified products.

In our online pharmacy, vigora is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

• Cross‑border purchasing is common for cost savings but carries regulatory, authenticity and warranty risks.
• Provincial drug plans may cover sildenafil for eligible patients; check Ontario Drug Benefit, BC PharmaCare and RAMQ for criteria.

Comparable Medicines And Patient Preferences (Alternatives In Canada, Checklist)

Alternatives available in Canada include tadalafil (Cialis), vardenafil (Levitra) and avanafil (Spedra).

• Pros/Cons Checklist For Conversations: efficacy, cost, onset/duration, contraindications, desired spontaneity, comorbidities and formulary coverage.
• Pharmacists should align patient preference with provincial coverage and available DINs for substitution.

Many Canadian patients value privacy and convenience, favouring mail order, while others prioritise in‑person counselling at local pharmacies.

FAQ Section

• Q: Can I buy Vigora in Canada without a prescription?
• A: No; a prescription is required in Canada, and Vigora as an Indian brand may not be Health Canada‑authorised, so check the Drug Product Database before import.
• Q: Will provincial drug plans cover sildenafil?
• A: Some public plans cover sildenafil for eligible patients or via special authorisation; verify Ontario Drug Benefit, BC PharmaCare and RAMQ for criteria.
• Q: Is sildenafil safe if I have heart disease?
• A: Use with caution; sildenafil is contraindicated with nitrates and in unstable cardiac conditions—consult cardiology if there is recent MI or severe angina.
• Q: Can I take sildenafil daily?
• A: Standard dosing is on demand; daily dosing should only be under medical supervision with a clear prescribing rationale.

Guidelines For Proper Use (Pharmacist Counselling & Provincial Tips)

• Confirm concurrent nitrates, alpha‑blockers and strong CYP3A4 inhibitors before dispensing.
• Review cardiovascular history and recent cardiac events; consider specialist referral when indicated.
• Advise on timing—take roughly 30–60 minutes before sexual activity and avoid taking more than one dose in 24 hours.
• Warn about alcohol and high‑fat meals delaying onset and increasing dizziness risk.
• Instruct to seek emergency care for priapism lasting more than four hours or sudden vision or hearing loss.
• Document DIN, lot number and patient consent in the record at dispensing.
• Advise against unverified online imports; purchases of Vigora from unverified suppliers carry authenticity and importation risk.

• Priapism: A persistent, painful erection lasting more than four hours; medical emergency requiring immediate attention.
• Nitrate Interaction: Combining nitrates and sildenafil can cause severe, life‑threatening hypotension and is an absolute contraindication.

Provincial Tips: provide French counselling materials in Quebec and ensure documentation for exceptional access requests when pursuing off‑label or chronic coverage through provincial formularies.

Delivery Across Canada (English)